- Tillerson confronts North Korea at UN
- Elysee plays down opulence of Macron birthday at Loire chateau
- Argentina fires head of navy over submarine tragedy
- Egyptian presidential hopeful apologizes to arrested supporters
- Argentina fires head of navy after submarine tragedy
- Canadian police probe mysterious deaths of billionaire pharma couple
- Nazareth Christmas celebrations will be held as normal: mayor
- Libyan coast guard rescues more than 250 migrants trying to reach Ital
- It looks like tax reform is already paying off with the GOP base
- Thousands of Romanians mourn former king Michael
- Sexual harassment allegations swirl around ESPN
- Report: Toronto billionaire and his wife found dead in their home
- Austrian conservatives bring far right into government
- Russian and French foreign ministers discussed situation in Syria
- Australian PM future safeguarded in crucial Sydney by-election
- Palestinian billionaire Masri detained in Saudi Arabia: sources
- Myanmar journalists' group to don black T-shirts over arrest of Reuter
- Dustin Hoffman accused of sexual assault
- Facebook worries it might be bad for you, adds a mute button
- U.S. says did everything possible to help Italy cyber investigation
Sanofi ends development of Clostridium difficile vaccine
(Reuters) - Pharmaceutical company Sanofi SA said on Friday that it had ended development of an experimental vaccine for Clostridium difficile infection, after an early look at late-stage trial results indicated a low probability for success.
About three million Americans are infected annually with the bacterium - also known as C. diff - which spreads mainly through hospitals, nursing homes and doctors’ offices.
As many as 30,000 Americans die each year from the bacterium, usually after recurrences of infection. The infections are typically the result of taking antibiotics, which wipe out friendly bacteria in the colon that normally keep C. diff under control.
Sanofi said in a statement that all data from vaccinated volunteers in the trial will continue to be analyzed for more information and shared with the scientific community.
The company said it will continue to focus on six other vaccine projects in development.
Reporting by Deena Beasley, Editing by Rosalba O'Brien
Our Standards:The Thomson Reuters Trust Principles.